Evidence-based peptide profiles
Every claim cited. Every evidence gap acknowledged. Plain-language profiles for people who want the real picture.
Last updated: March 2026
Semaglutide
GLP-1 Receptor Agonist (Ozempic, Wegovy, Rybelsus)
An FDA-approved GLP-1 receptor agonist for type 2 diabetes and weight management. One of the most extensively studied peptide drugs in history, with 25,000+ trial participants.
Tirzepatide
Dual GIP/GLP-1 Receptor Agonist (Mounjaro, Zepbound)
An FDA-approved dual GIP/GLP-1 agonist for type 2 diabetes, weight management, and sleep apnea. Head-to-head superiority over semaglutide for weight loss.
PT-141
Bremelanotide (Vyleesi)
An FDA-approved melanocortin receptor agonist for hypoactive sexual desire disorder (HSDD) in premenopausal women. Works through the brain to increase desire — a fundamentally different mechanism than PDE5 inhibitors.
Tesamorelin
Growth Hormone-Releasing Hormone Analog (Egrifta)
An FDA-approved GHRH analog for HIV-associated lipodystrophy. The only GHRH analog still FDA-approved. Emerging data for cognitive function and NAFLD/NASH.
Retatrutide
Triple GIP/GLP-1/Glucagon Receptor Agonist (LY3437943)
Eli Lilly's next-generation triple agonist in Phase 3 trials. Up to 28.7% weight loss (TRIUMPH-4) and A1C reductions of up to 2.0% in T2D (TRANSCEND-T2D-1). ~1,780 participants across five trials.
BPC-157
Body Protection Compound-157
A synthetic pentadecapeptide studied for tissue repair, gut healing, and recovery. Extensive animal data, very limited human evidence.
GHK-Cu
Glycyl-L-Histidyl-L-Lysine Copper(II) Complex
A naturally occurring copper tripeptide found in human plasma. Moderate evidence for topical skin rejuvenation; limited evidence for injectable forms.
Sermorelin
Growth Hormone-Releasing Factor (1-29)
A synthetic GHRH analog previously FDA-approved for pediatric growth hormone deficiency. The most accessible GH peptide with the strongest regulatory pedigree.
Thymosin Alpha-1
Thymalfasin (Zadaxin)
A 28-amino-acid thymic peptide approved in 35+ countries for hepatitis B/C and immune support — but not in the US. Decades of clinical use, 11,000+ subjects studied. The clinically validated sibling of TB-500.
Kisspeptin
KISS1 Neuropeptide (Kisspeptin-54/10)
The master regulator of reproductive biology. Being studied for IVF trigger (safer than hCG for OHSS prevention), hypothalamic amenorrhea, and fertility. Multiple Phase 2 trials with strong translational potential.
TB-500
Thymosin Beta-4 Fragment (17-23)
A synthetic heptapeptide fragment of Thymosin Beta-4. Studied for wound healing and tissue repair, primarily in animal models and equine medicine. Zero human trials for the fragment itself.
Selank
Synthetic Tuftsin Analog (TP-7)
A 7-amino-acid anxiolytic peptide approved in Russia since 2009. Reduces anxiety without sedation or dependence — a different approach than benzodiazepines. Limited Western clinical data.
Semax
ACTH(4-10) Analog — Nootropic Heptapeptide
A 7-amino-acid nootropic peptide approved in Russia since 2011 for ischemic stroke, cognitive disorders, and optic nerve atrophy. Listed on Russia's List of Vital & Essential Drugs. The cognitive counterpart to Selank.
CJC-1295
Drug Affinity Complex : Growth Hormone-Releasing Factor
A synthetic GHRH analog designed for sustained growth hormone elevation. Phase I data confirms activity; clinical development halted in 2006 after a participant death.
Ipamorelin
Selective Growth Hormone Secretagogue
The first selective growth hormone secretagogue — raises GH without elevating cortisol or prolactin. Failed its primary efficacy trial for postoperative ileus.
AOD-9604
Advanced Obesity Drug 9604 (hGH Fragment 177-191)
A synthetic fragment of human growth hormone designed for fat metabolism. Excellent safety record across 900+ participants, but failed its pivotal Phase IIb weight loss trial.
NAD+
Nicotinamide Adenine Dinucleotide
A naturally occurring coenzyme essential for cellular energy and repair. Not a peptide, but commonly sold alongside them. Compelling basic science, limited clinical evidence for IV therapy.
MOTS-c
Mitochondrial Open Reading Frame of the Twelve S rRNA type-c
A mitochondrial-derived peptide discovered in 2015 that's been called an 'exercise mimetic.' Strong mechanistic story and impressive mouse data — but essentially zero human clinical evidence yet.
KPV
Lys-Pro-Val (Alpha-MSH Fragment)
The smallest bioactive peptide in our database — just 3 amino acids. A fragment of alpha-MSH with anti-inflammatory properties, gaining traction for gut health. Promising animal colitis data, but zero human clinical trials.
Liraglutide
GLP-1 Receptor Agonist (Victoza, Saxenda)
The GLP-1 agonist that started it all. FDA-approved for type 2 diabetes (Victoza, 2010) and weight management (Saxenda, 2014). The LEADER trial was the first to show cardiovascular benefit for a GLP-1 drug. Daily injection, largely superseded by semaglutide for new prescriptions.
Oxytocin
Neuropeptide Hormone (Pitocin)
An FDA-approved peptide hormone with decades of obstetric use. Extensively studied for social cognition and mental health — but results are more complex than the 'love hormone' narrative suggests. On the WHO Essential Medicines List.
Elamipretide
Mitochondria-Targeted Peptide (SS-31 / FORZINITY)
The first FDA-approved mitochondria-targeted peptide. Granted accelerated approval for Barth syndrome in September 2025. Phase 3 trials ongoing for dry AMD and primary mitochondrial myopathy. A landmark for the mitochondrial peptide class.